<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041612</url>
  </required_header>
  <id_info>
    <org_study_id>RaMM-BO 2.0</org_study_id>
    <nct_id>NCT01041612</nct_id>
  </id_info>
  <brief_title>Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi</brief_title>
  <official_title>Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taewoong Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taewoong Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, randomized multicenter study is to determine whether there
      is any difference in stent patency of covered metallic stents in terms of stent positioning,
      above and across the sphincter of Oddi, in malignant bile duct obstruction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obstruction of 1st C-SEMS or presence of jaundice at death without stent exchange</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death of patients</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cancer of Bile Duct</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Group A: C-SEMS, inserted above SO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: C-SEMS, inserted across SO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTFE Covered ComVi [full covered] Biliary Stent</intervention_name>
    <description>The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.</description>
    <arm_group_label>Group A: C-SEMS, inserted above SO</arm_group_label>
    <other_name>PTFE Covered ComVi [full covered] Biliary Stent, Taewoong Medical, Korea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTFE Covered ComVi [full covered] Biliary Stent</intervention_name>
    <description>The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.</description>
    <arm_group_label>Group B: C-SEMS, inserted across SO</arm_group_label>
    <other_name>PTFE Covered ComVi [full covered] Biliary Stent, Taewoong Medical, Korea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inoperable and/or unresectable cases of malignant stenosis at distal common hepatic
             duct or CBD, &gt;= 18 years old

          -  Bile duct or gallbladder cancer invading CBD or distal CHD

          -  Pancreatic cancer with mid or distal CBD invasion

          -  Cancer should be 1.5 cm apart from bifurcation and 2 cm apart from ampulla of Vater.

          -  First attempt of endoscopic biliary metallic stenting

          -  Negative history of biliary tract surgery

          -  Life expectancy at least longer than 4 months (Karnofsky score &gt;60%)

        Exclusion Criteria:

          -  Ampullary cancer

          -  Klatskin tumor

          -  Combined intrahepatic bile duct cancer

          -  Patient with hemobilia

          -  Previous history of biliary drainage (endoscopic, percutaneous, surgical) except
             plastic stent or endoscopic nasobiliary drainage smaller than 7 Fr within 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Ki Lee, PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gifu University</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onomichi General Hospital</name>
      <address>
        <city>Onomichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teine-Keijinkai Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University</name>
      <address>
        <city>Ube</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University School of Medicine</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University School of Medicine</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Daegu School of Medicine</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University School of Medicine</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Jung Nam Cho, Jimin Han, Ho Gak Kim, IM Hee Shin, Sang Heum Park, Jong Ho Moon, Jin Hong Kim, Don Haeng Lee, Iruru Maetani, Hiroyuki Maguchi, Keiji Hanada, Ichiro Yasuda, Takao Itoi, Hiroyuki Isayama, Dongki Lee. Prospective Randomized Trial Comparing Covered Metal Stent Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction. Gastrointestinal Endoscopy 77(58): AB139-AB140, 2013</citation>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taewoong Medical Co., Ltd.</investigator_affiliation>
    <investigator_full_name>Jong Taek, Lee</investigator_full_name>
    <investigator_title>General manager</investigator_title>
  </responsible_party>
  <keyword>CBD</keyword>
  <keyword>HBD</keyword>
  <keyword>cancer of bile duct</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

